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Systemic administration of the ph otoactive drug 8-meth-
oxypsoralen to a group of mice bearing cutaneous allo-
grafts , followed by exposure to long-wave ultraviolet ra-
diation (UV A, 320- 400 nm) (PUVA) daily for 14 days at 
a site distant from the allograft , significantly in creased the 
survi val time of the allografts . This effect w as seen both 
in donor- recipient combinations that differ at the major 
histocompatibility complex and in those differing only at 
minor histocompatibility loci. Trea tment with 8-meth-
oxypsoralen or long-wave UV radiation alone was inef-
fec tive in prolonging allograft survival, as were doses of 
mid-wave UV radiation (UVB, 280-320 nm) that produced 
T he use of the photosensitizer 8-methoxypsoralen (8-M O P) in combination with long-wave UV radiation (UV A, 320-400 nm) (known by the acronym PUV A) has gained wide acceptance in medical practi ce for the treatment of a number of derm atologic condi tions, 
most notably pso rias is and the cutaneous lymphoma, mycosis 
fun goides [1-4]. Psora lens are linear three-ring heterocyclic com-
pounds that intercalate between DNA and RNA base pairs in the 
dark . T hey can then photo react with the 5, 6 double bond of 
pyrimidines in the presence of UV A radiation to yield cycload-
di tion products [5]. Bo th the furan and pyrone ends of the mol-
ecule can react; thus cross-links as well as monoadducts are in-
trodu ced into DNA and RNA [6-9]. Although these lesions can 
be mutagenic or cyto toxic [1 0), the widespread use of PUV A 
therapy in cl inical medicine has been associated with acceptabl cr 
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Abbreviatio ns: 
Con A: concanava lin A 
CTL: cyto toxic lymphocyte 
O N CB: d initrochlo robenzene 
FCS: fetal ca lf serum 
MHC : maj or his tocompatibility complex 
8-M OP: 8-methoxypsoralen 
PUV A: psoralen plus UV A 
SC: spleen ce ll (s) 
UV A: long-wave ultraviolet 
UVB: mid-wave ul traviolet 
greater inflammation than the PUV A protocol. Allo-
grafted, PUV A-trea ted animals also demonstrated de-
creased alloantigen reactivity aga inst don or-strain spleen 
cells during the period of treatment by cytotoxicity assays . 
Allografts of skin in the murine system are highly im-
munogenic and are generally rej ected faster than organ al-
lografts; thus PUV A treatment appears to exert a potent 
effect on prolon ging allograft survival. T he systemic nature 
of the effect and the fa ct that adverse side effects from 
PUV A are largely limited to the skin suggest that PUV A 
might have a role in clinical organ transplantation man-
agement . J In vest Dermatol 88:424-429, 1987 
adverse side effects to date. Short-term side effects include ery-
themogenic responses similar to sunburn when the dose of UV A 
radiation is not ca refully contro lled, and an apparentl y idiosyn-
chrati c response consistin g of a painful or itchy sensa ti on in the 
skin some hours after treatment. More serious side effects consist 
of a somewhat increased risk of nonmelano ma skin cancer de-
velopment after hundreds of PUV A treatments, primaril y in pa-
tients previ ously trea ted with an additional carcinogen, usually 
ionizing radiation l4,11], and clinical " aging" of the skin con-
sisting of hyperpigmentation, lentigo form ation , and wrinkling. 
The mechanism of action of PUV A therapy is unknown bu t 
is presumed to relate to an inhibition of DNA synthesis secondary 
to photoinduced DNA cross-linking [1] . Numerous cellular and 
animal studies have been performed to evaluate the biologic effects 
of PUV A treatment. These include a systemic suppression of the 
ability to sensitize mice to contact sensitizers, acco mpanied by 
the appearance of splenic antigen-specific T suppressor cells [1 2,13]. 
A similar effect on the indu ction of sensitivity to the topical 
allergen dinitrochlorobenzene (ON CB) has been described in hu-
mans with psorias is [1 4]. T his investiga tion involved ex posure 
of both the site of sensitiza tion and distant sites to PUV A; there-
fore, differentiati on of local from systemic effects w as not pos-
sible. T his study also demonstrated some diminution in the elic-
itation response to ONCB in previ ously sensiti zed psoriatic patients. 
Additionally, PUV A has been demonstrated to decrease the num-
ber and perturb the morph ology of the anti gen-presenting cell of 
the epidermis, the Langerhans cell (1 5). Investiga tions examining 
the phenotype o f peripheral blood lymphocytes in patients ex-
posed to ruv A have demonstrated that a single erythemogenic 
expos ure to PUY A results in a decrease in circul atin g T cells and 
B cells, with an increase in the proporti on of cell s w ithout B or 
T markers [1 6]. Patients with pso ri as is exposed to long-term 
PUY A trea tment have been demonstrated to have a decreased 
number of circulatin g helper pheno type (T4 +) T cell s [1 7]. These 
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va rio us o bse rva tio ns suggest th at PUVA treatm ent m ay have 
immuno log ic consequ ences th at could have therapeuti c impli-
ca tio ns. 
Ea rlier repo rts ha ve dem o nstrJted til Jt preexposure of allog rafts 
to PUV A th erap y 11 8 ,1 9J o r loca l ex posure of the site of skin 
graftin g pro lo ngs all ograft survi va l [201. Beca use preex posure o r 
loca l ex pos ure of an all ograft to PUV A mig ht produce dJ mage 
of fun cti o nal signifi ca nce, and beca use irradi atio n of an internal 
organ in situ is no t practi cJI , w e have eXJ min ed th e ro le o fPUVA 
therapy o f th e recipi ent in m odi fy ing all og raft rejectio n . 
We present here data dem o nstratin g that PUV A therapy of 
graft recipients m arkedl y prolo ngs the survi va l of skin allog rafts 
at a non irradiated site in geneti ca ll y defin ed mice both w hen th e 
dono rs and recipi ents differ at loci o f th e maj o r histoco mpatibility 
co mplex (MH C), and when onl y min o r histocompatibi lity dif-
ferences arc present. The systemi c natLIre of the effect sugges ts 
that it ma y be use fu l in pro lo ng in g the survi val o f internal o rg:lI1 
transplants. 
MATE RIALS AND M ETHODS 
Laboratory Animals Fem ale BALBlc (H_2d), 57BLl6 (H-
2b), A/j (H-2"), and B 10. A/SgSnj (1-1-2") mi ce we re o bta ined fro m 
the Jackson Labo rato ry (Bar H arbo r, Maine) . A/J and n 10. A/SgSnJ 
mi ce di ffer at a number o f mino r histoco mpatibility loci including 
H- l , 1-1-3, 1-1-4, H -7, and H-8. T he anim als were 8-14 weeks old 
at th e start of each ex periment and w ithin each ex perim ent the 
age o f the animal s did not vary by m o re than 2 weeks. T he mice 
had free access to Purina M o use how and chl o rinated wa ter and 
were housed in a fac ility where ambi ent li ght w as regul ated on 
a 12-h li g ht/ dark cycle . 
Skin Grafting Skin g raftin g was perfo rm ed by the method of 
Fisher and Kripke 1211· T he trun cal skin of dono r mi ce w as shaved 
and chemica lly depi lated (N eet, Whitehall LaboratOries, N ew York, 
N ew Yo rk) fo ll o w ed by sacrifi ce o f the anim als. Full-thickness 
skin w as o btained by sharp dissecti on o f trun ca l skin fo ll owed 
by removal o f fa t and panni culus ca rn osus by blunt dissection . 
Dono r g rafts m easured appro xim atel y 1 X 1.5 cm . Recipient 
mi ce were shaved and depi lated on the do rsum . Then they w ere 
anestheti zed w ith 0,1 ml of3.6% chlo ral h ydrate per 10 g of bod y 
weight ad mini tered i. p. A rectan g ul ar sectio n of skin measurin g 
approximately 0.75 X 1.25 cm w as removed from each m o use 
down to fasc ia fro m the g raftin g site. The grafts were applied to 
the fascia (dermi s side do wn) and a co ntinuo us row o f auto clips 
was applied around the edge o f each graft. 
Treatment of Graft Recipients G rafted mi ce were injected 
with 0.4 m g o f 8-M O P (H o ffm ann-La Roche, Nutl ey, N ew Jer-
sey) in 0.2 ml o f a 2% gel atin so luti on. The ventral surfaces o f 
the mice w ere then shaved with elect!'ic clippers and ex posed to 
UVA radiatio n by suspending the mice o n a large-m esh w ire 
screen 20 cm abo ve a bank of6 PU V A Au o rescent bulbs (Sylvania, 
Danvers, Massachusetts) filte red thro ug h a 0 .5 111m-thick sheet 
of M ylar to eliminate w aveleng ths in th e UVB ran ge «320 nm). 
A rectang ul ar area m eas urin g approximatel y 2.5 X 3.5 cm plus 
th e bo tto m o f the paws we re ex posed to UVA radiation . The 
Auence rate at the level o f the anim als was 14 W 1m 2 as m easured 
by an IL-700 research radi o m eter (In ternational Li g ht , N ewbu-
ryport, M as achusetts). Durin r irradiati o n, each m ouse w as iso-
lated in a pl as tic compartm ent to prevent irradi ati o n of the g raft 
site. o ntro l mi ce w ere treated with 8-MOP alo ne, UV A alone, 
or w ere untrea ted . 
Irradiation of mice wi th mid-wave UV radiation (UVB, 280-320 
nm) was perform ed in exactly the same m ann er except that 8-
MOP and the M ylar filter w ere o mitted and 6 FS40 sun lamps 
(Wes tin gho use, B loomfield, N ew j ersey) were substituted fo r 
PUVA bulbs. These lamps emit approximately 60% of their o ut-
put in the UVB range with a Au ence rate o f 3 W 1m 2 at the level 
of the anim als as m easured with an lL-700 resea rch radio m eter 
(Internati o nal Lig ht) . 
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Scoring of Graft Rejection G rafts we re exa mined dail y in a 
coded fas hi on and rej ectio n w as scored w hen 50% of the area o f 
the graft had undergone necro ti c degeneratio n as assessed by vis-
ual inspectio n o f the g rafts. Differences in survi val amon g gro ups 
was assessed by th e rank-sum tes t. 
Cytotoxicity Assay Recipient mice were sacrifi ced and a m o n-
ocellul ar suspension o f nucleated spleen cells (S ) w as prepared. 
Spleen cells fro m graft recipients were restimul ated in vitro b y a 
m eth od simi lar to th at o f Burako ff et al [22]. BrieAy, 7 X 106 
responder S w ere cocultured w ith I X lOr. erythrocyte- free x-
irradiated ( 1500 R) stimul ator do no r-strain splenocy tes in '16-mm 
tissue culture we lls (Linbro; Flo w Labo ratories, In c., M cLea n , 
Virg inia). ulture m edium consis ted o fHPMl1 640 supplemented 
w ith 10% heat-in acti va ted fetal ca lf serum (FC S), antibio ti cs (100 
U / ml penicillin and 100 fLg/ml strepto m ycin) , 2 I1lM L- glutamin e, 
I mM sodium pyruvate, nonessential amino acids (0.1 mM of 
each), and 5 X 10 - 5 M 2-mercaptoethano l. ultures were incu-
bated fo r 5 d ays at 37°C in a humidified atm os phere containing 
5% O 2 . 
Chromium Release Assay y to tox icity o f effector cells was 
assessed by using do no r-strain conca navalin A ( on A) lympho-
blasts as ta rge ts. Concan ava lin A blasts w ere prepared by a 2-day 
culture of2 X 107 SC in 10 ml of m edium containing 2.5 fLg/ ml 
o f on A (S ig m a hemi ca l Co. , St. Lo uis, Missouri). Labeling 
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Figure 1. A, utancous allograft surviva l. A/J mice were grafted wi th 
BALB/c skin. Treatmcnt of recipients: opell sql/ares, no trea tment (n = 
7); solid circles, 8-MO P i.p. (n = 6); solid sql;ares, UVA ra diation ex po li re 
(1500 J/ m2) (n = 6) ; Opell cil'dcs, 8-MO P plus UV A radiation (PUVA) 
(n = 5). T he survival of grafts in the PUV A trea tment grollp was sig-
nifi cantl y prolongcd compared to the other groups (p < 0.01). B, A /J 
micc were grafted with DALB/c skin . T reatmcnt of recipients: opell Sq,/(I/'CS, 
no trea tment (II = 5); opell rircles, 8-MO P plus UV A radiation (PUV A) 
(n = 5). (Symbols serve to diftcrcntiate curves; vertical drop in curves 
represent rcjcction(s) scored that day .) T he survival of grafts in rhe PUVA 
group was significantl y prolonged compared to the cont rol group (p < 
0.0 1). 
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of blast cells was performed by in cubation of 2 X 107 recove red 
cells w ith 150 j.(.1 o fN a51C r04 (2 mCi / m l; N cw E ng land Nucl ea r, 
Boston, Massach usetts) for 90 min. 
The isoto pe rei case assay was perfo rm ed in ro und-botto med 
microtitc r platcs (Dynatech Laboratories, Alexa ndria, Virg ini a) 
by the add iti on of se ri al d ilutions of effecto r cclls to 1 X 104S I Cr_ 
labeled ta rgct cell s in a tota l volumc of 200 j.(.1 minim al cssenti al 
med ium co ntainin g 5% FCS. T he platcs we re ccntri fuged (300 
g, 30 s) at thc beg inning of thc assay, incubatcd at 37"C for 3-4 
h, and centrifu gcd again (500 g, 10 min). A vo lum c o f 100 j.(.1 o f 
m ed ium was rcm ovcd from each wcll for ga mma countin g. Pcr-
cent spccifi c chro mium-5 1 release was co mputcd acco rdin g to thc 
fo rmul a (E - S)/( M - S) X 100% , in w hich E is th c isotope 
rclease in thc p rcsence of effector cel ls , S is th e spo ntaneous iso-
tope rei case in the presence of medium , and M is th e m ax im al 
releasc obta ined by addin g to thc targets an eq ual volume of 1 % 
Triton x-tOO. The results are reported as the mea n percent spe-
cific rel ease of dupli ca te meas uremen ts w ith negative determi-
nations reported as O. 
RES ULTS 
Effect of PUV A Treatment on Survival of MHC-Incom-
patible Cutaneous Allografts at a Nonirradiated Site To 
exa min e the possibl e ro le of PUV A in the pro longation of all o-
graft surviva l, A/J mi ce (H-2") were g rafted on th e do rsum with 
cutaneous allografts from BALBlc donors (H_2d). A/J and BALB/c 
mi ce differ at m any loci of the MHC. T he g rafted mice were 
divided into the fo llowin g groups: g roup 1, no trea tment; g ro up 
2, adm inistration 'of 8-MOP; g ro up 3, ex posure of the ventral 
surface of thc anim als to UV A rad iation (1500 J/ m2); and gro up 
4, ad minis trat io n of 8-MOP fo llowed by cx posure to UV A ra-
Fig ure 2. AI) mice grafted with BALBlc sk in . Esscntiall y in tact graft 
on PUV A-treated mouse (leji) contras ted with a rejected graft on an 
untrcated mouse ( ,·(~ /Il ) . 
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diati on (PUV A) . Trcatmcnt was beg un 1 day afte r graft in g and 
continued for 14 d ays . T his regimen res ulted in o nly mild sca lin g 
and hypcrkera tosis of PUVA-ex posed skin sites by day 14. Mi ce 
we re cxa m ined dail y for g raft rej ection. Figure 1 A shows that 
recipicnts treated w ith PUV A have signifi ca ntly longer allog raft 
sur viva l compared w ith other g ro ups (p < 0.01, PUVA g roup 
co mpared with the other g roups). 8-Methoxypsoralen o r UV A 
radi ation trea tm ent alone had no effect o n all ograft survival tim e. 
These results w ere confirm ed in the additi o nal experim ent shown 
in Fig 1 B. Figure 2 contras ts a rej ected g raft fro m the untrea ted 
g roup (right) w ith an essenti all y intact g raft fro m the PUV A 
g roup at day 19. As a techni ca l contro l, 6 A/J mice were grafted 
w ith isografts; these g rafts all survived indcfi nitel y. Also, 3 11 0 -
g raftcd mi ce trea ted with this rcgimen but witho ut hair rem ova l 
had no pro lo nga tion of g raft surviva l. T hu s, any stray li ght reach-
in g thc gra ft could not account fo r our findin gs. 
Prcliminary data (not shown) indi ca te that this PUV A protoco l 
does not inhibit th e dcvelopmen t of contact h ypersensiti vity to 
d initroflu o robcnzene when it is applied to a nonirrad iated site ] 
h after thc 14th P UVA ex posure with eli citat ion 7 days later. It 
is currcntl y un known w hethcr thi s pro toco l wou ld suppress the 
indu ction of contact hypersensitivity if started at the timc of or 
just aftcr immu niza ti on . 
Effect of UVB Radiation on Survival of MHC-Incompat-
ible Cutaneous Allografts To exa m inc the specificity of the 
PUV A cffcct o n allog raft surviva l, an cxperiment was designed 
to cxa minc w hether equall y infl amm atory doses of UVB rad iation 
would have any effect o n all ograft surviva l. Ultraviolet B radi a-
tion (280-320 nm) is th c waveband responsible for m ost of the 
crythem ogcni c res po nse to natu ral sunlig ht [231. Preliminary ex-
pcrim cnts detcrmin ed that 3600 J/ m2 of UV B radiation from FS40 
sun lamps had approx imately thc sa m c infl ammatory effect on AI] 
micc as l 500 J/m 2 in o ur PUVA pro toco l after sevcral ex posures 
(data not shown). A/J mi ce w ere g rafted o n the do rsul11 with 
BALBlc skin and d ividcd in to 2 g roups. O nc g roup received 
daily UV B ex pos ure (3600 J/ m2) to the ventral surfa ce for 14 da ys 
startin g 1 day after g raftin g, whil e the o th er g ro up was untrca ted. 
Fig ure 3 c1ca rl y shows th at thi s UVB rad iat io n t rea tm ent had no 
cffcct on allograft survival. An add itio nal experiment was per-
fo rm cd usin g a dose of UV B rad iat ion suffi cient to cause crusting 
and supcrfi cial eros ions at irradiated sites by 14 days. Twelvc A/J 
mi cc wcrc g rafted with BALBlc skin o n the do rsa l surface and 
d ivided . O ne group received 5400 ]l m 2 of UVB irradi ation to 
thc ventra l surface dai ly for 14 days as above, w hile th e other 
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Figure 3. Cutaneous allograft surviva l. AI) mice were grafted with BALB/c 
sk in. Treatment of recipients: ope" sq"nres, no trea tment (n = 5); ope" 
circles, UV B radiation ex posure (n = 5). No signi fica nt difference in the 
surviva l of the allografts was seen between the two groups. 
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Figure 4. Cut~neou s 311 0gr3ft surviva l. Af] mice werc gr~fted w ith B IO.A 
skin. Trc3tmcnt of rec ipients: OpCII sqllm·cs, no treatment (n = 6) ; OpCII 
circles, 8-M O P plus UVA radiation (PUVA) (n = 7) . T he surviv31 of 
g rafts in th e PUV A group was signifi ca ntl y pro longed co mpared to the 
other g ro ups (p < 0.0 1). 
group was untreated . T his dose of UVB radiation also fa il ed to 
prolo ng a ll og raft survival (mea n survival ± SEM for the treated 
group 16.6 ± 0.9 days vs 14.2 ± 1.4 days fo r the contro l). 
Effects ofPUV A on Survival of Minor Histocompatibility-
Disparate C utaneous A llografts AI] (H-2') and B10.A (H-
2') mi ce are MH C-identica l but d iffer at a number of min o r 
histocompatib ili ty .Ioci. In the fo ll owing experiment, AI] recip-
ients were g rafted o n the dorsum w ith B10.A skin. T he grafted 
mice w ere d ivided into 2 treatment gro ups: g ro up 1, no trea tm ent; 
group 2, admini stratio n ofS-M O P fo llowed by ex pos ure to 1500 
Jlm2 of UV A r3d iat io n (PUV A). As above, the mi ce were trea ted 
dai ly for 14 days st3rti ng 1 day after g raftin g, and they were 
exa min ed da il y fo r g raft rejectio n . Fig ure 4 clea rl y shows th at 
recip ients tre3 ted with PUV A have sig ni fi c3 ntf y pro longed al-
lograft sur viva l co mpared to contro ls. 
Grafted Mice Treated with PUVA Demonstrate Decreased 
Splenic Cytotoxic Activity Against Donor-Strain Targets 
To examine antid o no r cytotoxic ac tivity, some AI] mi ce bea ring 
BALB / c skin g rafts we re s3cri ficed on day 7 of PUV A therapy, 
2 h after th e 7th PUV A treatment alo ng w ith non-PUV A-treated 
contro ls for cy totoxic lymphocy te (CTL) ass3ys. Host spleno-
cytes were restim ub ted in vitro fo r 5 days in th e presence of 
donor-strain nucleated Sc. Stimulated splenocytes were then tested 
for their abilit y to lyse dOll o r-strain t3rgets in a 4-h chromium-
51 release assay . T he d3ta in Tab le I show that splenocy tes h3r-
ves ted from 3]J ografted , PUVA-trea ted m ice have substantiall y 
Table I. C ytotox icity of Recipient Sp leen ells (SC) Aga inst 
BALB/c Targets 
Percent Spcciflc Lys is' 
Group" PUV A Treatm ent" EfT: 33 : I II: I 
46. 7 27.4 
(pos contro l) 
2 + 12.2 3. 1 
3 N ongrafted , no ntrea tcd 22.9 7.7 
(neg contro l) 
' A /j mi ce were g rafled wi th BALBlc skin in g ro ups I and 2. 
' PUVA-trca ted recipients wc re g ivcn 0.4 nt g ofS-MO P in 0.2 Illi of a 2% gelatin 
solutio n by i. p. injecrio n dail y for 7 da ys startin g 24 h after g raftin g. Fifteen minut es 
after injectio n. the shaved ventra l surrace of cach 311 im :1 1 was ex posed to 1500 J/ m2 
of UV A radiatio n. A ll mi ce we re sacrifi ced and assays beg un 2 h after the 7th PUV A 
exposure. Res tirnnlatio n was w ith BAUVc Sc. 
(Ta rgets werc DALE/c blasts. Spontaneous isoto pe release was < 25(¥o. 
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Table II. Cy totoxicity of Recipi en t Spleen Cells (SC) Against 
C57BLl6 T argets 
G ro up" 
2 
3 
PUVA 
Treat l11 cnt" 
+ 
N o ng raftcd. 
Immuniza tio n with 
C57BLl6 SC' 
+ 
+ 
nomrca tcd (neg contro l) 
Percent Specifi c 
Lys i " 
EfT: 33: 1 11:1 
44.5 
44.3 
11 .4 
33.4 
29.6 
6.2 
·' A /j mi ce were g rarted wi th BALBlc skin in g ro ups I and 2. 
"PUV A trea tm ent as in footnote to T:lblc I except treattn ent W:1S continued dai ly 
fo r 14 da ys. 
(Five days after the last PUVA trC:1tmcn t. thc mice were injected wi th 3 X 107 
ery th rocy te-free, x-irradiated 57BLl6 SC subcutaneously. Seven da ys arter il11-
1t1lIlliz:ltioll . mice Were sacrificed and assays begun . Resti mulatio ll was with C57BL/6 
Sc. 
JTa rgc ts we re C57 13L/6 concall:1va lin A b la sts. Spontaneous isoto pe release \vas 
< 25%. 
less cytotoxic activ ity aga inst BA LB/c targets compared with cells 
fro m gr3fted , non-PUV A- treated mice. In fact , the cells fro m 
PUV A-treated mi ce show less act ivity than the negative control; 
thc cyto toxicity seen in thc negative groups m ay be g rea ter than 
zcro due to som e in vitro priming durin g the 5-day cul ture period . 
To exa min e th e immunocompetence of an imals after a course 
o f therapy, g ro ups of PUV A- treated and non-PUV A- treated AI] 
mi cc bearing BALB/c skin g rafts were immunized to C57BLl6 
SC, 5 days afte r the treated g roup fin ished a 14-day course of 
PUV A-therapy. In agree ment w ith the data shown above, the 
trea ted g roup Iud signifi cantl y longcr allograft survival comparcd 
with the untreated contro l g roup (dat3 not shown)'. Seven days 
latcr , mice were sacrifi ced and a C TL assay perfo rm ed as 3bove 
aga inst C57BLl6 targets. The data in Table " show that by 5 
days 3fter the end of PUV A tfler3py, trea ted graft recipients are 
able to be both scnsiti zed w ith and express imm un ity to a new 
all oa ntigen. 
DISCUSS IO N 
T hc understandin g and mana gement of transplantation and graft 
to ler:\I1 ce arc areas of g reat importance in cf inicalmedi cine. Dem-
onstrat ion of th e essen tial role o f ly m phocytes in graft rejection 
dates back to the earl y work of Medawar and his associates 124,25]. 
Tra nsplal1tation managem ent is gener311 y condu cted by suppres-
sion of th e host immune system to allow graft toleran ce. T hree 
bas ic approaches have bcen uti.Iized : (1) drug-induced immuno-
suppression; (2) to tal ly mphoid x-irrad iation; and (3) anti-T-cell 
antibody therapy. Althoug h both irradiatio n and dru g immu-
nosuppression therapies have proved successful in the manage-
m ent of closely matched g rafts r26-28], they have proved less 
reliable in less closely m atched g rafts , at least in reg imens not 
using cycfospo rin [29], and present many undesirable side cffects 
3S a rcsul t of their b ck of specifi city . Anti-T-cell antibod y therapy 
is in its infancy, 31tho ugh its re lative specificity suggests the pos-
sibility of certain adv3 ntagcs, particul arl y with rega rd to side 
effects . 
T his report demonstrates that PUV A treatment sys tcmicall y 
pro longs the surviva l of cutaneous allografts bo th when the do-
no r- recipien t combinatio n is mi sm atclwd at the MHC and w hen 
o nl y minor histocompat ibility differences are present. Decreased 
reactivity of the host against graft determinal1ts was confirmed 
with the CTL assay. T he effect of PUV A treatm ent was seen 
despite the fact that no th erapy was ad ministered beyond day 14 
after graft ing. T he systemic nature of this effect is of grea t im-
po rtance; it suggests that PUV A treatment mig ht also be useful 
in prolonging th e surviva l of allografts of internal o rgans. As 
mentioned previo usly , a g rea t dea l of experien ce has been clini-
call y obtained w ith PUV A in the trea tm ent of va rious skin dis-
428 GRANSTEIN, SMIT H , AN D PARRISH 
eases 11 -4] and undesirable side effe cts ha ve been accepta ble and 
limited to the skin . Indeed , th e direct effects of PUV A therapy 
are limited to the depth o f penetration of the UV A radiation 
photons (essentially restri cted to th e skin in hum ans) . This sug-
gests th at, if PUV A proves to be a useful adjuvant modality in 
the m anage ment of organ transplants, it may be rel ati vely free 
fro m serious systemi c adverse effects. A sa fe adjun ctive therapy 
may be quite useful in redu cing th e dosage of other elements of 
a th erapeuti c regimen to redu ce adverse side effects and, o f course, 
to enh ance the efficacy of the regimen. Such studies are in progress 
in animal m odels. It is important to note, however, that o ther 
modalities of chroni c immunosuppression in humans are asso-
ciated with an increased risk of skin cancer [30-36); since PUV A 
is a cutaneo us ca rcinogen [4,11] th e use of PUV A in co mbination 
w ith other immunosuppressive agents m ay lead to an increased 
risk of skin ca nce r even if PUV A all ows for smaller dosages o f 
these o th er agents. 
T he m echanism of action of PUV A in prolonging allograft 
survival is unknown. Although a lack of reactivity of the host 
against g raft determinants is evident, we have not established 
whether this results from a fai lure of sensiti za tion or down-reg-
ulati on of the effecto r and o f the immune res ponse. A number 
of hypoth eses may account for the activity of PUV A in sup-
pressing rejection of the allografts. PUV A may, by virtue of 
inducing infl ammation, alter the traffi ckin g patterns of immu-
nocompetent cells with functiona l consequences. However, the 
fa ilure of doses of UVB radiati on that produ ce grea ter cutaneous 
infl ammation than the PUV A doses used in these studies to have 
an effect on g raft survival wo uld argue against a simple ca use and 
effect re lationship between inflammation and the immuno-
suppression o bserved . PUV A therapy may directly affec t lym-
phocy tes as they circulate through the mi crovasculature o f the 
sk in , ca using them to be perturbed in such a way that they ca nnot 
be sensitized to alloa ntigens. An additiona l possible mechanism 
would in vo lve th e rel ease of a mediator(s) by targets in th e skin 
affected by PUV A that circulate and render the host immune 
sys tem un ab le to recogni ze and/o r be activated by alloantigens. 
At this tim e, th ere is no direct evidence supportin g any of these 
hypotheses. Of course, PUV A m ay be exerting more th an one 
relevant effect. 
C utaneous all og rafts are highl y immunogeni c; they are gen-
era ll y rejected faster than organ allografts [37]. Factors contrib-
utin g to the rapid rejection of skin g rafts are thought to include 
the extensive nonspecifi c infl ammation ca used by dam age to the 
dermis and the large degree of ischemic nec rosis in the immediate 
postg raftin g period , since the cutaneous vasculature is not anas-
tomosed to the host [37]. Thus the effect o f short-term PUV A 
treatment seen in this repo rt is quite pronounced . 
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